EmbeddingGemma 2: an open, lightweight multimodal embedding model
deepmind.google·6d ago
AI Engineering
Hacker News·Aug 15·5 min read
First human trials of designer protein therapies stun US neuroscientists
TL;DR
Recent human trials in China using chemogenetic therapies based on designer receptors, known as DREADDs, have shown promising results, potentially revolutionizing neuroscience treatments.
✦ Why It Matters
Explore potential applications of DREADDs in your research or clinical practice today.
Key Takeaways
- Investigate DREADDs for potential applications in your research.
- Consider the implications of chemogenetic therapies in clinical settings.
- Stay informed about ongoing trials in China and their outcomes.
- Evaluate the risks associated with viral vector gene therapies.
How It Works
DREADDs are engineered receptors that, when activated by a specific drug, can selectively suppress neuronal signaling in targeted brain circuits. This allows researchers to manipulate brain activity with high precision, minimizing off-target effects common with traditional drugs.